Status:
COMPLETED
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
To assess the safety and tolerability, characterize the dose limiting toxicities (DLTs) and identify the maximally tolerated dose (MTD) of Elotuzumab administered in combination with either Lirilumab ...
Detailed Description
Allocation: * Part1: Non-randomized * Part2: Randomized
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
- Inclusion Criteria:
- Subjects must have histological confirmation of multiple myeloma with measurable disease (per International Myeloma Working Group (IMWG) criteria):
- Relapsed/refractory multiple myeloma, subjects who are post autologous transplant and have achieved very good partial response (VGPR) or complete response (nCR) with minimal residual disease (MRD)
Exclusion
Key Trial Info
Start Date :
December 9 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 10 2017
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT02252263
Start Date
December 9 2014
End Date
October 10 2017
Last Update
November 1 2017
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Arkansas For Medical Sciences
Little Rock, Arkansas, United States
2
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States, 21287
3
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
4
The Ohio State University
Columbus, Ohio, United States, 43210